PAUL STEVEN M — SEC insider filings
SEC reporting owner CIK 1237564. 25 insider filings on record with FilingPulse; latest filed 2026-10-22.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2020-12-22 to 2026-10-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 3 filings — 79,744 shares, $2,251,654 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 11 legs across 2 filings — 30,000 shares, $4,660,371 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 58.
- Largest priced transaction: sale of 15,000 shares @ $140.00 ($2,100,000) in ALNYLAM PHARMACEUTICALS, INC., filed 2020-12-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 3 | — | 11 legs · 30,000 sh · $4,660,371 | 5 |
| Rapport Therapeutics, Inc. (RAPP) | Director | 4 | 3 legs · 77,380 sh · $2,001,389 | — | 2 |
| Karuna Therapeutics, Inc. (KRTX) | Director | 8 | 2 legs · 2,364 sh · $250,264 | — | 38 |
| Sage Therapeutics, Inc. (SAGE) | Director | 8 | — | — | 8 |
| Seaport Therapeutics, Inc. (SPTX) | Director | 1 | — | — | 4 |
| Voyager Therapeutics, Inc. (VYGR) | Director | 1 | — | — | 1 |
Insider filings — PAUL STEVEN M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-22 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 35,714 @ $27.28 | EDGAR |
| 2026-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Conversion (C): 67,031 · Grant/award (A): 12,258 (derivative) @ $0 · Grant/award (A): 991,192 (derivative) @ $0 · Conversion (C): 210,526 (derivative) @ $0 | EDGAR |
| 2025-09-15 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 28,284 @ $24.50 · Purchase (P): 13,382 @ $24.97 | EDGAR |
| 2025-06-18 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 21,850 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Karuna Therapeutics, Inc. (KRTX) | Disposition to issuer (D): 2,046 @ $330 · Disposition to issuer (D): 8,550 @ $330 · Disposition to issuer (D): 30,304 @ $330 · Disposition to issuer (D): 10,000 @ $330 · Disposition to issuer (D): 33,882 @ $330 · Disposition to issuer (D): 30,304 @ $330 · +12 more | EDGAR |
| 2024-03-04 | 4 | Karuna Therapeutics, Inc. (KRTX) | Other (J): 47,378 @ $315.18 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · +1 more | EDGAR |
| 2024-02-26 | 4 | Karuna Therapeutics, Inc. (KRTX) | Option exercise (M): 27,510 @ $7.27 · Option exercise (M): 4,008 @ $99.72 · Option exercise (M): 27,510 (derivative) @ $0 · Option exercise (M): 4,008 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Karuna Therapeutics, Inc. (KRTX) | Tax withholding (F): 804 @ $317.14 | EDGAR |
| 2024-01-04 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 3,971 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Karuna Therapeutics, Inc. (KRTX) | Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Grant/award (A): 11,400 @ $0 · Grant/award (A): 22,800 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 2,395 (derivative) @ $0 | EDGAR |
| 2022-11-30 | 4 | Sage Therapeutics, Inc. (SAGE) | Other (J): 5 @ $38.17 | EDGAR |
| 2022-06-17 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 9,947 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 15,000 @ $11.33 · Sale (S): 253 @ $166.04 · Sale (S): 4,948 @ $168.95 · Sale (S): 4,872 @ $169.71 · Sale (S): 1,235 @ $171.16 · Sale (S): 1,434 @ $172.10 · +6 more | EDGAR |
| 2022-02-17 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 146,900 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 1,638 (derivative) @ $0 | EDGAR |
| 2021-11-12 | 4 | Sage Therapeutics, Inc. (SAGE) | Other (J): 1 @ $43.36 | EDGAR |
| 2021-08-18 | 4 | Karuna Therapeutics, Inc. (KRTX) | Purchase (P): 1,183 @ $105.63 · Purchase (P): 1,181 @ $106.10 | EDGAR |
| 2021-07-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,032 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Voyager Therapeutics, Inc. (VYGR) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-24 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 161,850 (derivative) @ $0 | EDGAR |
| 2020-12-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 15,000 @ $9.30 · Sale (S): 15,000 @ $140 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1237564 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs